NEW YORK, August 10, 2017 /PRNewswire/ --
If you want a Stock Review on ABBV, AZN, BMY, or JNJ then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. For today, DailyStockTracker.com reviews four major players in the Drug Manufacturers space, and they are: AbbVie Inc. (NYSE: ABBV), AstraZeneca PLC (NYSE:
Shares in North Chicago, Illinois-based AbbVie Inc. rose 0.77%, ending Wednesday's trading session at $72.02. The stock recorded a trading volume of 4.53 million shares. The Company's shares have gained 0.25% in the last one month, 9.15% over the last three months, and 15.01% on an YTD basis. The stock is trading 1.27% and 10.94% above its 50-day and 200-day moving averages, respectively. Moreover, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 54.34.
On August 03rd, 2017, AbbVie announced that the US Food and Drug Administration approved MAVYRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes. MAVYRET is an eight-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment. Visit us today and access your complete report on ABBV for free at:
Cambridge, the UK headquartered AstraZeneca PLC's stock declined 0.94%, closing the day at $29.47 with a total trading volume of 4.12 million shares. The Company's shares have advanced 7.87% since the start of this year. The stock is trading 2.57% below its 200-day moving average. Additionally, shares of AstraZeneca have an RSI of 31.16.
On August 01st, 2017, AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, announced that the US Food and Drug Administration had granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma, who have received at least one prior therapy. Acalabrutinib is an investigational, highly selective, potent Bruton tyrosine kinase inhibitor in development for the treatment of multiple B-cell cancers.
On August 09th, 2017, research firm Investec upgraded the Company's stock rating from 'Hold' to 'Buy'. The complimentary research report on AZN can be accessed at:
Bristol Myers Squibb
On Wednesday, shares in New York headquartered Bristol-Myers Squibb Co. recorded a trading volume of 7.63 million shares, which was higher than their three months average volume of 7.50 million shares. The stock ended the day 0.86% higher at $57.40. The Company's shares have advanced 3.74% in the past month and 4.10% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.02% and 4.42%, respectively. Furthermore, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 62.08.
On August 03rd, 2017, Bristol-Myers Squibb and IFM Therapeutics announced that they have signed a definitive agreement under which the former will acquire all of the outstanding capital stock of the latter, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity, and inflammatory disorders. The companies anticipate the transaction will close during Q3 2017. Register for free on DailyStockTracker.com and download the research report on BMY at:
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock gained 0.73%, finishing yesterday's session at $133.23. A total volume of 5.76 million shares was traded, which was above their three months average volume of 5.71 million shares. The Company's shares have advanced 1.52% in the last one month, 8.48% in the previous three months, and 15.64% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.47% and 8.66%, respectively. Additionally, shares of the Company, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 52.90.
On July 21st, 2017, research firm BTIG Research downgraded the Company's stock rating from 'Neutral' to 'Sell', with a target price of $110 per share.
On August 04th, 2017, Johnson & Johnson announced that it will participate in the 2017 Wells Fargo 12th Annual Healthcare Conference on September 06th, 2017, at The Westin Boston Waterfront in Boston, MA. Alex Gorsky, Chairman and CEO, and Dominic Caruso, Executive Vice President, CFO, will represent the Company in a session scheduled at 10:00 a.m. ET. Get free access to your research report on JNJ at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All